[
  {
    "ts": null,
    "headline": "Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?",
    "summary": "Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=82271ce54ea5345b9142c7d260fc5faf0b5c2e296a6299fa7ec4c963996eda9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741966235,
      "headline": "Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?",
      "id": 133185352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=82271ce54ea5345b9142c7d260fc5faf0b5c2e296a6299fa7ec4c963996eda9d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
    "summary": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
    "url": "https://finnhub.io/api/news?id=1abe98a94a5099519afa678fad5327d6aa411241faf00be9fb4307183a812db2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741961322,
      "headline": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
      "id": 133184265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
      "url": "https://finnhub.io/api/news?id=1abe98a94a5099519afa678fad5327d6aa411241faf00be9fb4307183a812db2"
    }
  },
  {
    "ts": null,
    "headline": "Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?",
    "summary": "Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?",
    "url": "https://finnhub.io/api/news?id=50ce28934705859f25b678dfe2b97d74e33fb2a303d230fc72b67034a56bea08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741959600,
      "headline": "Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?",
      "id": 133191249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?",
      "url": "https://finnhub.io/api/news?id=50ce28934705859f25b678dfe2b97d74e33fb2a303d230fc72b67034a56bea08"
    }
  }
]